FCS Trial Navigator

Select Clinic:
Select Cancer Type:
Select Line of Therapy:
Select Trial Status:
Search Protocol Info:
ProtocolTitle
ABI-007-MBC-001
BRE 223
Phase 2/3 Open-Label, Randomized Study of Weekly nab-Paclitaxel with Gemcitabine or Carboplatin Compared to Gemcitabine/Carboplatin as First Line Trea ...
CMEK162A2301
MEL 36
Randomized Phase III, Open Label, Two-Arm Study Comparing the Efficacy of MEK162 versus Dacarbazine in Patients with Advanced Unresectable or Metastat ...
I4C-MC-JTBC
LUN 252
A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Ac ...
IPI-145-07
CLL30
Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CA184-156
LUN 223
Randomized, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Newly Diagnosed Exte ...
1200.167
LUN 247
A Phase IIIb, non-randomized, open-label, two-cohort study in patients with EGFR mutations-positive advanced adenocarcinoma of the lung, assessing the ...
2010-01
LYM 75
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma who are Poor Candidates for R-CHO ...
2012-002
MM 36
A Phase 2 Study of Weekly Carfilzomib in Combination with Dexamethasone for Progressive Multiple Myeloma
391101
RM 269
A PHASE 1 OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BAX69 IN SUBJECTS WITH MALIGNANT SOLID TUMORS
59R5-003
LUN 244
A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer also now ...
AG221-C-001
HR 36
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-2 ...
AT13387-04
GU 102
A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no ...
B 43
B 43
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Du ...
B 47
B 47
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorub ...
BIND-014-005
LUN 248
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Admini ...
BO25114
GI 185
Double-Blind, Placebo-Controlled, Randomized Phase 3 Study of Pertuzumab in Combination with Trastuzumab and Chemotherapy in Her2-Positive Metastatic ...
BRE 166
BRE 166
Use of the PRO Onc Assay to Assess HER2 Amplification and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Stand ...
BRE 186
BRE 186
Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
BRE 197
BRE 197
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast ...
BRE 200
BRE 200
Phase II Study of Cabazitaxel plus Lapatinib as Therapy for Her2-Positive Metastatic Breast Cancer Patients with Intracranial Metastases
BRE 233
BRE 233
Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab plus Pertuzumab plus a Taxane Following Anthracyclines versus Trastuzumab E ...
BRE 234
CLEE011A2301
A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with HR+, Her2-N ...
BRE115532
MEL 31
Phase III Randomized Double Blind Study of Dabrafenib in Combination with Trametinib versus 2 Placebos in the Adjuvant Treatment of High-Risk BRAF V60 ...
BVD-523-01
RM 286
PHASE I DOSE-ESCALATION, SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF BVD-523 IN PATIENTS WITH ADVANCED MALIGNANCIES
C14015
RM 280
Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in ...
C25003
LYM 84
A Randomized, Open-Label, Phase 3 Trial of A+AVD versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma
C32496/1105
RM 309
An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients with Advanced Solid Tumors in Phase 1 and in Patients with Advanced Melano ...
CA204-006
MM 30
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myelom ...
CAMN107A-US37
CML 22
Phase 2 Randomized Study of Treatment-Free Remission in CML in Chronic Phase Patients who Achieve and Sustain MR4.5 after Switching to Nilotinib
CLL 18
CLL 18
Phase II Trial of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
CNS 13
CNS 13
Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma ...
CO-338-010
RM 259
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast Cancer or O ...
COMETI-P2-2012.0
BRE 218
Phase 2 study of Characterization of CTCs from subjects with Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index
CRAD01Y2201
BRE 217
Randomized, Open Label, Phase II Study of Everolimus in Combination with Exemestane versus Everolimus Alone versus Capecitabine in the Treatment of Po ...
D2270C00005
BRE 196
A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally ...
D3610C00003
GU 86
A Phase Ib, Multicentre Study of AZD5363 Monotherapy to Assess the Anti-tumour Activity, Safety, Tolerability and Pharmacokinetics in Metastatic Castr ...
DLM-10-001
CNS 14
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of DAG in Patients With Recurrent Malignant Glioma
EMR200592-001
GI 179
Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination with TH-302 Compared with Gemcitabine in Combinatio ...
FRF4998g
HR15
An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients with Relapsed or Refractory ...
GI 148
GI 148

View Slide
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
GI 166
GI 166
Phase II Study of 5-Fluorouracil, Oxaliplatin and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized ...
GI 168
GI 168
A Phase II Study of 5-Fluorouracil, Aflibercept, and Radiation in the Preoperative or Adjuvant Treatment of Patients with Stage II / III Rectal Cancer
GI 184
GI 184
A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of Gemcitabine plus Nab-Paclitaxel Combined with OGX-427 or Placebo in Patients with M ...
GO27802
BRE 220
A PHASE Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF GDC-0032 IN COMBINATION WITH EITHER DOCETAXEL OR PACLITAXEL IN PATIENTS ...
GO27826
MEL 30
Phase III, Randomized, Double-Blind Placebo-Controlled study of Vemurafenib Adjuvant Therapy in Surgically Resected, Cutaneous BRAF-Mutant Melanoma at ...
GO27983
GU 89
Phase 2 Study of GDC-0068 with Abiraterone Acetate versus Abiraterone Acetate Alone in Patients with Castration-Resistant Prostate Cancer Previously T ...
GO28141
MEL 32
A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAFV600-Mutation Positive ...
GO28609
GYN 43
A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
GS-US-296-0101
RM 294
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemoth ...
GS-US-313-0124
LYM 85
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated I ...
GS-US-339-0102
LYM 89
A Phase 2 Open Label, Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Patients with Relapsed or Refractory Hem ...
HHBB
RM 208
A Phase 1 Dose Escalation Study of LY2940680 in patients with Advance Cancer (Lilly HHBB)
HR 35
HR 35
A PHASE I OPEN-LABEL, MULTI-DOSE, DOSE ESCALATION STUDY OF PRT062070 IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
HR34
HR 34
An Open-label, Phase 1 Study of Bendamustine (B), Rituximab (R) or BR in Combination with IPI-145 in Subjects With Select Relapsed or Refractory Hemat ...
INCB 18424-144
RM 293
A PHASE 1B STUDY OF THE SAFETY AND TOLERABILITY OF RUXOLITINIB IN COMBINATION WITH GEMCITABINE WITH OR WITHOUT NAB-PACLITAXEL IN SUBJECTS WITH ADVANCE ...
INCB 18424-258
MPN 02
An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythem ...
IPI-145-06
LYM 87
A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma
LT1009-Onc-002
GU 100
Phase 2 Open-Label,Single-Arm Study of Asonep Administered as a Single Agent to Subjects with Refractory Renal Cell Carcinoma
LUN 229
LUN 229
Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed with or without OGX-427 in Previously Untreated Stage IV Non-Squamous NSCLC
LUN 231
GO27912
Phase II, Double-Blind, Placebo-Controlled, Randomized Study of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab with and without GDC-094 ...
LUN 258
LUN 258
Phase II, Single-Arm Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
MDV3100-08
BRE 211
A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide (formerly MDV3100) in Patients w ...
MDV3100-11
BRE 222
Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients with Advanced, Androgen Receptor-Po ...
MDV3100-12
BRE 229
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Enzalutamide in Combination with Exemestane in Patients with A ...
MEI-003
MDS 14
Phase 2 Randomized, Placebo-Controlled Study of Pracinostat in Combination with Azacitidine in Previously Untreated IPSS Intermediate Risk 2 or High R ...
MEL 41
MEL 41
A PHASE Ib, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF MPDL3280A ADMINISTERED IN COMBINATION WITH VEMURAFENIB IN PATIENTS WITH PREVIOUSLY UNTR ...
ML28257
BRE 208
ML28257/BRE208 An Observational Study of Treatment Patterns and Outcomes in Patients with Her2 Positive Metastatic Breast Cancer
ML28442
GI 181
FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
MM 27
MM 27
Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
MM 45
MM 45
A Multicenter, Randomized, Open-Label Non-comparative Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients with Relapsed and Refractory M ...
MM-111-13-02-04
GI 182
Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with or without Trastuzumab in Patients with Traditional and Non-Traditional Her2 Expre ...
OGX-011-12
GU 92
Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Meta ...
PAM4983g
RM 245
A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF GDC-0068 IN COMBINATION WITH DOCETAXEL, FLUOROPYRIMIDINE PLUS OXALIPLA ...
PMT4979g
RM 275
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid ...
PR-30-5010-C
BRE 236
Breast Her2-, BRCA+, 2nd or 3rd line Niraparib vs single agent chemo Phase 3, Randomized Trial of Niraparib versus Physicians Choice in Previously Tre ...
PR-30-5011-C
GYN 40
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
RM 187
RM 187
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Advanced Solid Malignancies Followed by a ...
RM 188
RM 188
A Phase 1 Study of LY2606368 in Patients with Advanced Cancer
RM 289
RM 289
An open-label, randomized, 2 treatment, 2-period, 2-way crossover, single-dose study to determine the relative bioavailability of the MEK inhibitor, t ...
RM 312
RM 312
A Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MS ...
RM 320
RM 320
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Me ...
RV-FOL-GELARC-0683C
LYM 77
Phase III Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab + Lenalidomide versus Rituximab + Chemotherapy Followed by Ritux ...
SCRx16-001
LUN 249
Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients with ...
TGR-1202-101
HR 31
A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR-1202 in Patients with Relapsed or Refractory Hematologic Malignancies
VS-4718-101
RM 307
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VS-4718 in Subjects with Metastatic Non- ...
WO29074
GU 108
Phase 2, Randomized Study of MPDL3280A as Monotherapy or in Combination with Bevacizumab versus Sunitinib in Patients with Untreated Advanced Renal Ce ...
X82-CLI-101
RM 226
A Phase I, First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Subjects with Advanced Solid Tum ...